Zoekresultaten - You searched for Medical Technology

629 results

argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology

Read more

argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

Read more

FairJourney Biologics announces an innovative technology to discover antibody molecules in full therapeutic format

Read more

MyCartis to engage in point-of-need testing with the ANTELOPE Dx platform technology

Read more

Imec and CARDIS Partners Develop Unique Photonic-Based Medical Device for the Screening

Read more

Mindbytes expands to North America to develop next generation serious medical games driven by artificial intelligence

Read more

TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform

Read more

ViroVet receives grant from VLAIO (Flanders) to boost the development of its disruptive vaccine technology

Read more

Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors

Read more

Bone Therapeutics Strengthens Board of Directors

Read more

Novosanis’ medical device Colli-Pee® prefilled with urine preservative now CE-certified

Read more

Gene technology today: a practical approach

Read more

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

Read more

Celyad announces new agreements with Celdara medical and Dartmouth College

Read more

2nd Symposium : « Introduction of the Next-Generation-sequencing technology in routine analysis in the Belgian healthcare »

Read more

Imec Reports Micro-Optomechanical Pressure Sensor Advancing Pressure Monitoring in Biomedical Applications

Read more

Imec Packs New Fast Eye Tracking Technology into Ergonomic Design for High-Quality AR/VR Experiences

Read more

Bionection

Read more

Free coaching session: I want to develop a medical device

Read more

Bone Therapeutics Business Update for First Quarter 2017

Read more

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform

Read more

bionection – Partnering Conference for Technology Transfer in Life Sciences

Read more

Bone Therapeutics announces H1 results for 2017

Read more

Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

Read more

Bone Therapeutics Business Update for Third Quarter 2017

Read more

Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline

Read more

Ablynx appoints dr. Robert Friesen as Chief Scientific Officer

Read more

Bone Therapeutics Reports Full Year 2017 Results

Read more

Open Innovation Day with Boston Scientific

Read more

Sequana Medical raises €27.5 million in successful Initial Public Offering

Read more

Fluidda and Materialise announce partnership to develop personalized solutions for lung patients

Read more

JLABS Info Session Webinar

Read more

Novosanis signs an agreement to provide MDxHealth a customized urine collection device

Read more

ONTOFORCE and Ghent University launch a new innovative ‘text mining’ project

Read more

TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week

Read more

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

Read more

Cochlear acquires exclusive licence to Artificial Intelligence assistant

Read more

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Read more

TiGenix Launches Global Phase III Trial for Cx601

Read more

TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis

Read more

MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test

Read more

TiGenix strengthens US operations with senior appointments

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

Imec Leverages the Power of Silicon Fabrication to Create Innovative Neural Probe Demonstrator with Unprecedented Electrode Density

Read more

MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer

Read more

Imec Designs and Fabricates World-First Miniature Neural Probe for Simultaneous Recording of Multiple Brain Regions at Neuronal Resolution

Read more

For the second year in a row ProDigest wins the Life Science Technology Award in the Deloitte Technology Fast 50 Competition

Read more

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla(TM) platform

Read more

Imec demonstrates direct optical reading of single-molecule DNA bases in modified nanopores

Read more

GST raises EUR 5 million to develop veterinary stem cell products

Read more

Imec demonstrates compact low-power 140GHz CMOS radar with on-chip antennas

Read more

TiGenix announces a change in its Board of Directors and its Management Team

Read more

ProDigest has been nominated for the Deloitte Technology Fast 50

Read more

Novosanis Colli-Pee approved by Mexican health authority

Read more

Promethera Biosciences Announces Investment by ITOCHU Corporation and a Broad Strategic Collaboration to Access the Asian Markets

Read more

Novosanis acquired by Orasure Technologies Inc

Read more

Imec and TNO Launch Comfortable, Disposable Health Patch with Long Battery Life to Measure Vital Signs

Read more

ProPharma Group Announces the Acquisition of The Weinberg Group

Read more

Brain imaging AI leader icometrix raises $18 million in new funding

Read more

Info day: I want to learn about the Medical Technology industry

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Read more

Helena Biosciences to develop automated blood test for chronic liver disease based on VIB and Ghent University research

Read more

Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®

Read more

BCCM training: New developments in gene and plasmid technology

Read more

Bone Therapeutics Notice of Half Year 2017 Results

Read more

Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer

Read more

MDxHealth Announces First Half 2017 Financial Results

Read more

Genohm announced today the signing of several new clients

Read more

flanders.bio - CMAST Partner Day: Realizing Life Science Innovation with Impact

Read more

Bone Therapeutics reports strong interim results from ALLOB® Phase IIA spinal fusion study

Read more

Bone Therapeutics announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis

Read more

Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017

Read more

Genohm: ISO 9001:2015 Certification - It’s a Big Deal

Read more

Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany

Read more

New start-up Aelin Therapeutics secures 27M Euros to pioneer the development of a novel drug modality

Read more

Bone Therapeutics Launches Equity Placement

Read more

Bone Therapeutics Provides Update on Equity Placement

Read more

Ablynx strongly believes unsolicited conditional proposal from Novo Nordisk fundamentally undervalues the company and its future prospects

Read more

Imec’s SWEET study Collects World’s Largest Dataset on Stress Detection

Read more

PharmaFluidics raises 7.3 million euro to expand commercialization of novel micro-chip device for biomarker, diagnostics and drug development applications

Read more

Bone Therapeutics provides business outlook and announces its financial calendar for 2018

Read more

Colli-Pee recognized at the prestigious Henry Van de Velde Awards

Read more

new England biolabs® and Bluebee partner to deliver an end-to-end data analysis solution for Nebnext direct® target enrichment

Read more

Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®

Read more

Bone Therapeutics strengthens Board with the appointment of Jean Stéphenne as Chairman

Read more

MDxHealth financial results

Read more

Trapping multidrug-resistant bacteria in molecular glue

Read more

Biocartis announces 2017 results and 2018 outlook

Read more

Bone Therapeutics announces private placement of convertible bonds

Read more

Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement

Read more

UgenTec: announcing our $ 9.3 million Series A funding

Read more

VIB: Molecular details of protein crystal nucleation uncovered

Read more

Bone Therapeutics Notice of Full Year 2017 Results

Read more

Bone Therapeutics Strengthens Board with the Appointment of Claudia D’Augusta as Non-Executive Director

Read more

Bone Therapeutics Business Update for First Quarter 2018

Read more

Bone Therapeutics Information on the total number of voting rights and shares

Read more

Israeli endoscopy startup 3NT Medical announces initial closing of $15M to include key strategic investor

Read more

Bone Therapeutics: preliminary documents for the Annual Ordinary and the Extraordinary General Shareholder Meeting

Read more

Bone Therapeutics: Information on the total number of voting rights and shares

Read more

Bone Therapeutics announces results of Annual General Meeting

Read more

argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation

Read more

Bone Therapeutics Notice of Half Year 2018 Results

Read more

Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study

Read more

Bone Therapeutics to present at 26th Annual Meeting of the European Orthopaedic Research Society

Read more

Bone Therapeutics announces single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis

Read more

Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer

Read more

BioWin Day 2018

Read more

Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD

Read more

Bone Therapeutics announces conclusions from interim analysis of Phase III PREOB study in hip osteonecrosis

Read more

Domus Medica and VITO collaborate on preventive health care

Read more

Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position

Read more

IQVIA, QbD and Select enter into a strategic partnership with flanders.bio as of January 1st, 2019

Read more

Information on the total number of voting rights and shares

Read more

Pharmafluidics’ new product launch steers ‘on-a-chip’ separations of complex biological samples to new heights

Read more

Sequana Medical announces the Coverage of the Base Offering of Its Initial Public Offering on Euronext Brussels

Read more

Sequana Medical NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES

Read more

Bone Therapeutics Notice of Full Year 2018 Results

Read more

Oxurion NV Business Update - FY 2018

Read more

VIB: Edible antibodies to treat and prevent gastrointestinal disorders

Read more

V-Bio Ventures leads AgomAb Therapeutics’ 21m EUR series A financing round

Read more

flanders.health

Read more

5 Flemish universities reveal innovative state-of-the-art biotech research at knowledge for growth 2019

Read more

Sequana Medical announces presentation of positive DSR clinical proof-of-concept data demonstrating potential in volume overload due to heart failure

Read more

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa

Read more

Bone Therapeutics successfully raises EUR 8.5 million

Read more

Hospital 3D printing conference - Save the date

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

Esperite N.V. with CryoSave contributes to treating a 9 year old child with thalassema major in Switzerland

Read more

Aratana Therapeutics Provides Update on ENTYCE®

Read more

TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York

Read more

FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®

Read more

TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas

Read more

Overnight skin care

Read more

Researchers discover mechanism behind rapid smell source localization

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York

Read more

Daily Newsflash- 14/06/17

Read more

Swissmedic has accepted for review the file on Cx601 for the treatment of Crohn's disease patients

Read more

TiGenix opens US headquarters in Cambridge, MA

Read more

eTheRNA immunotherapies advances In-Vivo mRNA Cancer Immunotherapy into first Oncology Clinical Studies

Read more

SelectMDx to be Distributed Across Middle East by IPS Genomix

Read more

Delphi Genetics receives GMP accreditation for plasmid DNA bioproduction

Read more

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Read more

TiGenix obtains commercial production license for expanded manufacturing facility

Read more

Life sciences meets micro-nanoelectronics: zooming in on MEDICAL DEVICES

Read more

TiGenix to participate and present at key investor and business development meetings

Read more

Dutch Life Sciences conference

Read more

Participation by Capricorn Venture Partners completes ViroVet’s series A funding

Read more

TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting

Read more

Dinner with Chef Watson

Read more

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

Read more

MyCartis appoints Philippe Stas as CEO

Read more

TiGenix strengthens European IP protection around lead development program Cx601

Read more

TiGenix announces partial conversion of bonds

Read more

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

Read more

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

Read more

MedFIT - Fostering Innovation in medTech

Read more

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease

Read more

Confo Therapeutics enters into drug discovery collaboration with Roche

Read more

Takeda announces its intention to acquire TiGenix

Read more

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 (darvadstrocel) in the treatment of complex perianal fistulas in Crohn’s disease

Read more

Imec Introduces CMOS Chip With 16,384 Micro-electrodes and 1,024 Channels for Multimodal Cell Interfacing

Read more

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Read more

European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects

Read more

Argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases

Read more

DuPont and Inbiose Celebrate EU Regulatory Approval of Their First Human Milk Oligosaccharide Ingredient for Infant Formula

Read more

Promethera Biosciences Announces Updates to its Board of Directors

Read more

Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates

Read more

Promethera Biosciences Raised Additional EUR 9.3 Million to Advance a Broad Product Pipeline in Severe Liver Diseases

Read more

argenx to receive third preclinical milestone payment from collaboration with LEO Pharma

Read more

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

Read more

argenx reports first quarter 2018 financial results and provides business update

Read more

Imec Presents Novel Organ-on-Chip Platform for Drug Screening

Read more

Gilead and Galapagos announce results with filgotinib in the phase 2 equator study in psoriatic arthritis and progression into phase 3 for the selection study in ulcerative colitis

Read more

Mithra signs binding heads of terms for commercialization of Estelle® in South Korea with women's health specialist Hyundai Pharm

Read more

Microbiome pioneer S-Biomedic secures investment and collaboration with global skin care company beiersdorf

Read more

Novosanis obtains regulatory approval for Colli-Pee in Brazil

Read more

ISTA Congress London

Read more

GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT

Read more

Qarad nominated twice for TOPRA Awards

Read more

Imec Releases Neuropixels Neural Probe to the Global Neuroscience Community

Read more

Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Read more

The Brain Mosaic: Cellular heterogeneity in the CNS (2nd edition)

Read more

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals

Read more

Mithra signs exclusive license and supply agreement for vaginal contraceptive ring in Australia and New Zealand

Read more

Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property

Read more

Microbiome pioneer S-Biomedic completes series A round with DSM Venturing

Read more

Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Read more

ActoBio Therapeutics™’ CTO Lothar Steidler Elected VIB Alumni Awardee 2019

Read more

Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

Read more

Wanted: 18,200 highly skilled profiles for bottleneck sectors

Read more

argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day

Read more

Bart Van Acker (Quality by Design) verkozen tot Jonge Vlaamse Ondernemer

Read more

PMV is stepping into a strategic partnership with flanders.bio as of June 1st, 2019

Read more

BioBase4SME Natural Fibertastic Workshop aims to encourage SMEs to apply for fully funded Bio-Innovation Coupons for fibre application testing

Read more

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia

Read more

Biocartis Group NV: Biocartis establishes US subsidiary and appoints US General Manager

Read more

New Study Shows MDxHealth's SelectMDx Test is Cost-Effective for Biopsy Selection

Read more

argenx receives first preclinical milestone payment in AbbVie collaboration

Read more

Biogazelle offers unique mRNA sequencing on plasma

Read more

Genohm at ISBER 2017 in Toronto

Read more

Biocartis Group NV: Biocartis Q1 2017 Business Update

Read more

ThromboGenics NV : New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

Read more

MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics

Read more

MDxHealth Trading Update: January to April 2017

Read more

ThromboGenics Business Update - Q1 2017

Read more

SelectMDx for Prostate Cancer Guides Patient Selection for mpMRI

Read more

SLims by Genohm integrated with Pathomation’s PMA.core

Read more

ViroVet and GALVmed to collaborate on novel vaccines for sheep & goats

Read more

Mithra & Gynial sign commercialization agreement for MyringTM in Austria

Read more

ThromboGenics NV to present THR-317 Pre-clinical Research Findings

Read more

Celyad obtains additional US patent for cancer treatment

Read more

Smart Implant & (Bio-)medical Imaging Platform Meeting

Read more

Biocartis wins prestigious Galenus Prize with its Idylla(TM) NRAS-BRAF Mutation Test for colorectal cancer

Read more

ThromboGenics to Present the Industry Pipeline of DME Treatments

Read more

Mithra Receives Orphan Drug Designation from EMA for E4 in Neonatal Encephalopathy

Read more

TiGenix announces final equity payment for cardiac platform acquisition

Read more

Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference – San Diego, June 19- 23, 2017

Read more

Aphea.Bio aims at leading position in next generation agricultural biologicals

Read more

argenx receives second preclinical milestone payment in collaboration with LEO Pharma

Read more

Celyad publishes additional pre-clinical data in support of THINK trial

Read more

TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland

Read more

iTeos Therapeutics Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development

Read more

Ablynx & Sanofi enter into a strategic collaboration to develop nanobody product candidates

Read more

Ablynx receives fast track designation from the FDA for Caplacizumab for the treatment of acquired TTP

Read more

MDxHealth Appoints Seasoned EVP to Lead Sales Force Expansion

Read more

UgenTec receives €50.000 grant by European Union

Read more

Ablynx announces 2017 half year results and year-to-date business update

Read more

Dosing of First Patient with investigational agent OMO-1

Read more

Celyad Reports First Half 2017 Financial Results and Operational Progress

Read more

Genohm releases new SLIMS overview video

Read more

Biocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO

Read more

MDxHealth Prepares for Growth with Executive Team Expansion

Read more

Biocartis announces H1 2017 results

Read more

SelectMDx Outperforms PCA3 Stratifying Men for mpMRI

Read more

PharmaFluidics appoints Fasha Mahjoor as independent director

Read more

Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

Read more

R-Biopharm AG & UgenTec partner to develop software for automated PCR analysis

Read more

Galapagos werft aan

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis

Read more

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

Read more

BioFIT 2017

Read more

Ablynx announces positive topline results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP

Read more

Ablynx files registration statement for a proposed global offering

Read more

MDxHealth Opens New Service and Research Laboratory in The Netherlands

Read more

Seminar: How Real World Data will change your clinical development to the better

Read more

Mithra Announces Completion of Recruitment in Donesta® Phase II Study

Read more

Networking

Read more

Ablynx announces launch of proposed global offering

Read more

Bridging Preclinical and Clinical Development

Read more

Ablynx - Notice in Relation to the Convertible bonds due May 2020

Read more

Ablynx announces full exercise of underwriters' option to purchase additional shares and end of stabilization period

Read more

Ablynx closes $200 Million Initial Public Offering in the United States

Read more

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

Read more

Ablynx closes on underwriters' option to purchase $30 million of additional shares in the U.S. initial public offering

Read more

MDxHealth Nine Month Trading Update

Read more

ThromboGenics Strengthens Leadership Team

Read more

Ionis Pharmaceuticals licenses novel antisense drug for the treatment of centronuclear myopathy to dynacure

Read more

Life Sciences Baltics 2018

Read more

Biocartis Group NV: Idylla(TM) Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference

Read more

Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE

Read more

Ablynx announces results for the first nine months of 2017 and a year-to-date business update

Read more

MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain

Read more

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Read more

Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests

Read more

Fast Track Diagnostics and UgenTec announce new interpretation software for all FTD real-time PCR multiplex kits

Read more

Follow-up info flanders.bio-CMAST Partner Day

Read more

The Adecco Group Announces the Acquisition of CMAST

Read more

Medical Biotechnology

Read more

7/12/2017

Read more

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Read more

BioFIT 2018

Read more

Ablynx reports additional clinically important benefits of Caplacizumab from its Phase III Hercules Study in acquired TTP

Read more

Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Read more

Mithra and Adamed Sign Commercialization Agreement for MyringTM in the Czech Republic

Read more

Galapagos - Update on progress in cystic fibrosis programs

Read more

Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies

Read more

Galapagos - Positive topline results with GLPG1972 in osteoarthritis patients

Read more

Ablynx announces board changes

Read more

UgenTec and MDxHealth sign partnership agreement for software to support interpretation of molecular test results

Read more

Sanofi to acquire Ablynx for €3.9 Billion

Read more

Press Release - Life Sciences & Biotechnology - 2/02/2018

Read more

Connect met Digital Health Start-ups

Read more

Ablynx announces 2017 full year results

Read more

Key Considerations in Health Care Product Development

Read more

CMAST to participate in the bio-europe spring partnering conference

Read more

VIB Plant-derived volatiles may serve as future antifungals

Read more

Argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies

Read more

MITHRA and ALVOGEN sign LSA for vaginal contraception ring in Russia

Read more

European scientists unite to track all cells in the human body

Read more

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

Read more

flanders.bio - Roche Diagnostics Partner Day 2018: ’Towards high-quality Cell Therapy’

Read more

Previously announced tender offers by Sanofi to acquire Ablynx will commence on april 4, 2018

Read more

argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

Read more

ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

Read more

ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data

Read more

VIB presents its 2017 annual results and confirms its reputation as global player

Read more

argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

Read more

Biocartis Q1 2018 business update

Read more

Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018

Read more

Agilent Technologies to Enhance Lab Informatics with Acquisition of Genohm

Read more

Ardena acquires Syntagon and strengthens API offering

Read more

flanders.bio - NBN event: Standards for Biotech

Read more

ThromboGenics Business Update - Q1 2018

Read more

flanders.bio Ghent becomes biotechnology capital of europe

Read more

ProDigest: PROMISE

Read more

Press Release - Life Sciences & Biotechnology - 23/05/2018

Read more

ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149

Read more

Mithra announces further positive phase IBB Donesta® efficacy and safety data

Read more

MDxHealth launch agreement with Philips for prognostic prostate cancer biomarker

Read more

argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis

Read more

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

Read more

UgenTec opens US sales office

Read more

argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris

Read more

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients

Read more

Genohm: SLIMS Version 6.2 has been Released

Read more

INNOVATION TRANSFORMING HEALTH CARE

Read more

Mithra Obtains First Marketing Authorization for Myring™ in Europe

Read more

Xendo and its affiliate, Sofus Regulatory Affairs AB have been acquired by ProPharma Group

Read more

Biocartis Group NV: Study Abstract on Performance of Idylla(TM) RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US)

Read more

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Read more

Start with the end in Mind – Healthcare Market Access in the Digital Age

Read more

argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody

Read more

argenx receives feedback from Japan's PMDA on Phase 3 clinical trial

Read more

Bioprocessing in the future: Single-Use and Continuous

Read more

Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla(TM) Platform in China

Read more

Ardena expands nanomedicine capabilities

Read more

Industry Insiders on the Future of Biopharma/Biotech in Belgium

Read more

ThromboGenics Business Update - H1 2018

Read more

argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

Read more

Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of DME

Read more

Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients

Read more

PharmaFluidics Facilitates Ultra-high-resolution Proteomics Analysis Through Agreement with Thermo Fisher Scientific

Read more

ViroVet wins pitching competition

Read more

Oxurion NV Business Update - Q3 2018

Read more

Oxurion NV to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinical Update at the American Academy of Ophthalmology 2018 Annual Meeting

Read more

ERS Genomics and Syngulon Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications

Read more

Inbiose secures €4 million in debt financing

Read more

New project launched to harmonize Clinical Data and develop a 21st Century Ecosystem for Real World Health Research in Europe

Read more

Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis

Read more

JLABS @ BE Info Session (webinar)

Read more

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Read more

flanders.health ideation workshop

Read more

Invitation: flanders.health workshop & Life-on-chip event

Read more

Fibrocor and Galapagos sign partnership in fibrosis

Read more

Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

Read more

Blockbuster Potential in Perimenopause with new E4 Candidate and Acceleration of Donesta Phase III Program

Read more

Biocartis Group NV: Biocartis and Nichirei Bioscience Announce Commercialization Collaboration for Japanese Market

Read more

AgroSavfe Announces Adrian Percy As New Independent Board Member

Read more

Aphea.Bio is awarded a 1.2Mi€ grant from VLAIO to further expand its activities

Read more

Call for project ideas on Personalised Medicine

Read more

Mithra Strengthens Management Team With Key Appointments

Read more

Evotec and Galapagos enter into collaboration in the field of fibrosis

Read more

MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis

Read more

MDxHealth Appoints Michael K. McGarrity as CEO

Read more

Mithra Announces New Polymer Technology Development for a Leading Veterinarian Company

Read more

Biocartis Places Its 1,000th Idylla(TM) Instrument with Geisinger in US

Read more

VIB, CD3 and Beactica announce drug discovery alliance targeting inflammatory diseases

Read more

argenx to receive first clinical milestone payment for product candidate developed under option agreement with AbbVie

Read more

Mithra receives Orphan Drug Designation from FDA for E4 in neonatal encephalopathy treatment

Read more

Oxurion NV announces full enrollment of its Phase 2 trial for treatment of DME, ahead of schedule

Read more

Novosanis enters into distribution deal with Fujirebio

Read more

GSK meets Belgian universities: Regional scientific associations bring together researchers from industry and universities

Read more

MouSensor is now Yesse Technologies

Read more

Biocartis Group NV: Biocartis Announces Global Collaboration with Covance

Read more

Vlaanderen investeert in gepersonaliseerde geneeskunde

Read more

New social, ethical & economic impact studies and activities developed by Sanquin

Read more

Mindbytes bvba publishes first peer-reviewed manuscript on its serestm methodological framework and demonstrates proof-of-concept

Read more

Scientists (dis)solve a century-long mystery to treat asthma and airway inflammation

Read more

The future of healthcare is digital

Read more

ViroVet and Pirbright join forces to develop African swine fever antivirals

Read more

eTheRNA: Appointment of Chief Financial Officer

Read more

Health Tech Platforms: Bringing Innovation to Market

Read more

Effective & Business Value-Oriented Patents

Read more

Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

Read more

VIB-KU Leuven: Duvel Moortgat opens scientific pilot brewery and presents BSSH Awards to Sir Paul Nurse, 2001 Nobel Laureate

Read more

Single-Use Event 2018: Bioprocessing in the future: Single Use and Continuous

Read more

Jo Bury, VIB selected as member of the EIC Pilot Advisory Board

Read more

Confo Therapeutics en DyNAbind bundelen krachten in de zoektocht naar nieuwe geneesmiddelen

Read more

ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes

Read more

AgroSavfe appoints Patrice Sellès as new Chief Executive Officer and further strengthens leadership team

Read more

Imec to Honor Samsung’s Dr. Kinam Kim With “Lifetime of Innovation Award”

Read more

Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee

Read more

Belgian PCR interpretation software company UgenTec partners with multiplex molecular diagnostics innovator PathoFinder

Read more

Kiadis Pharma announces positive regulatory update on ATIR101™ and ATIR201™

Read more

Member Directory

Read more

Argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

Read more

13th International Conference on Renewable Resources & Biorefineries

Read more

Next-Generation Antibodies and Protein Analysis (2nd Edition) - A VIB TOOLS & TECHNOLOGIES CONFERENCE

Read more

Applied Bioinformatics in Life Sciences (2nd edition)

Read more

Promethera Biosciences Presents Preclinical Data on Novel H2Stem Cell Therapy at EASL International Liver Congress

Read more

argenx files registration statement for a proposed public offering in the United States

Read more

argenx announces results of Annual General Meeting 2017

Read more

Celyad initiates second dose escalation in THINK trial in first US patient

Read more

MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx

Read more

argenx reports first quarter 2017 financial results and provides business update

Read more

VIB: A new unexpected key player in melanoma development identified

Read more

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

Read more

argenx announces launch of proposed initial public offering in the United States

Read more

VIB: Shortage of progranulin is a frequent cause of frontotemporal dementia

Read more

VIB: Researchers identify nutrient metabolism that drives breast tumor metastasis

Read more

Mithra to Initiate PK Study for Estelle®

Read more

argenx announces size of initial public offering in the United States increased to 5 million ADSs

Read more

argenx raises approximately $100 million gross proceeds with NASDAQ IPO

Read more

argenx announces full exercise of underwriters' option to purchase additional ADSs

Read more

Tau prevents synaptic transmission at early stage of neurodegeneration

Read more

argenx announces closing of NASDAQ IPO

Read more

Scientists give tumor-fighting cells a boost in battling bone marrow cancer

Read more

QbD voegt QbD Software toe aan 360°-service in kwaliteitsmanagement

Read more

argenx to Present at JMP Securities Life Sciences Conference

Read more

argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas

Read more

Software as a Medical Device

Read more

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Read more

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Read more

Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada

Read more

Membership Information

Read more

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein

Read more

Industrial automation companies from Baden-Württemberg looking for collaborations

Read more

Celyad announces initiation of the SHRINK trial

Read more

Novel perspectives on anti-amyloid treatment for the prevention of Alzheimer’s disease

Read more

TiGenix: Transparency Information

Read more

argenx to Present at Wedbush PacGrow Healthcare Conference

Read more

ALTIUS Pharma & Life Sciences seminar

Read more

argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results

Read more

Scientists unravel role of glutamine synthetase in the spread of cancer

Read more

argenx announces publication of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116

Read more

argenx reports second quarter business update and half-year 2017 financial results

Read more

ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB

Read more

Trainings - CONNECT / EDUCATE

Read more

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship

Read more

Promethera Biosciences to Present at Several International Partnering and Scientific Conferences this Fall

Read more

Camel-IDS appoints Ruth Devenyns as Chief Executive Officer

Read more

Press Release - Life Sciences & Biotechnology

Read more

Press Release flanders.bio

Read more

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Read more

Scientists pinpoint surprising origin of melanoma

Read more

Newly described process in Parkinson’s protein as a potential new therapy route

Read more

Ablynx prices $200 million Initial Public Offering in the United States

Read more

argenx reports third quarter 2017 financial results and provides business update

Read more

argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017

Read more

argenx to Present at Upcoming Investor Conferences

Read more

De Clercq & Partners seminar 2017

Read more

Promethera Biosciences Provides Update on Executive Management Team

Read more

JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix

Read more

Scientists shed light on a tumor-suppressive protein In metastases

Read more

argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

Read more

argenx announces launch of proposed public offering in the United States

Read more

argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering

Read more

BIO Investor Forum

Read more

IMPACT of the Bio Base Europe Pilot Plant in industrial biotechnology

Read more

argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million

Read more

Patient centricity in Clinical Research

Read more

TiGenix Transparency notification pursuant to Article 14 of the Law of May 2, 2007

Read more

TiGenix - Transparency Information

Read more

TiGenix - Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials

Read more

Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration

Read more

HDAC6 inhibitors protect against neuronal damage and have therapeutic potential in both neurology and oncology

Read more

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Read more

Argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018

Read more

Rousselot innovation days 2018

Read more

Imec.istart is ranked fourth in UBI Global’s University Business Accelerator ranking

Read more

argenx reports fourth quarter business update and full year 2017 financial results

Read more

Argenx to Present at Cowen & Company 38th Annual Health Care Conference

Read more

Internationalisatie voor Medtech & Biotech Start-Ups

Read more

Sell Your Science: Best Practices for Developing an Effective Non-Confidential Pitch Deck

Read more

Invite to flanders.bio's Salary Survey

Read more

VLAIO kent QbD subsidie toe voor innovatie in celtherapie procesontwikkeling

Read more

Networking - 14/06/2018

Read more

argenx announces Annual General Meeting of Shareholders on May 8, 2018

Read more

Press Release - Life Sciences & Biotechnology - 30/03/2018

Read more

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

Read more

TiGenix Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

Promethera Biosciences to Present New NASH Data at Two International Scientific and Partnering Conferences in April

Read more

argenx appoints Keith Woods as Chief Operating Officer

Read more

Hamilton Robotics first company to join the UgenTec’s new Molecular Automation Network

Read more

Promethera Biosciences Presents Novel Data on HepaStem’s Ability to Reduce Key Disease Parameters in Advanced Stage NASH in vivo Model

Read more

Galapagos announces ISABELA Phase 3 program in IPF

Read more

Reminder: Invite to flanders.bio's Salary Survey

Read more

Human Biotech & Animal Health Business Partnering Summit

Read more

Promethera Biosciences Establishes Branch Office in Tokyo

Read more

CoBioRes receives a € 1.7M grant from VLAIO to support its tetrapeptide prodrug research for treatment of Triple Negative Breast Cancer

Read more

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Read more

argenx selected for BEL 20 Index

Read more

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

Read more

argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018

Read more

Antwerps bedrijf QbD nu ook aanwezig in Zuid-Amerika

Read more

argenx receives second preclinical milestone payment under its development agreement with AbbVie

Read more

SCK•CEN seminar to discover the latest innovations in nuclear medicine

Read more

Internationalisation 24/09/2018 - 26/09/2018

Read more

Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix

Read more

Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF

Read more

argenx receives milestone payment from strategic collaboration with Shire

Read more

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Read more

argenx to host conference call & webcast to report second quarter business update and half year 2018 financial results on August 2, 2018

Read more

Press Release - Life Sciences & Biotechnology - 26/07/2018

Read more

Promethera Biosciences Appoints Mutsuki Takano as General Manager of its Branch Office in Tokyo

Read more

The FAMPH has published the Compendium on Biobank legislation

Read more

argenx to Present at 2018 Wedbush PacGrow Healthcare Conference

Read more

Lessons in Herding Cats: Business Development for Life Science Companies

Read more

argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis

Read more

Gilead and Galapagos announce filgotinib meets primary and all key secondary endpoints in first phase 3 study in rheumatoid arthritis

Read more

MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Read more

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Read more

argenx announces launch of proposed public offering in the United States

Read more

Genesis 2018

Read more

Press Release - Life Sciences & Biotechnology - 18/09/2018

Read more

argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering

Read more

argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million

Read more

Mithra Finalizes Contract for the Commercialization of Estelle® with South Korean Women's Health Leader Hyundai Pharm

Read more

Scale up! It’s time to grow for biotech companies!

Read more

ONTOFORCE and ChemAxon facilitate linked chemical data search

Read more

Galapagos phase 3 data on filgotinib in biologic-experienced rheumatoid arthritis to be presented at 2018 ACR/ARHP annual meeting

Read more

Galapagos: Positive trial results with filgotinib in psoriatic arthritis and ankylosing spondylitis both published in the lancet

Read more

argenx reports third quarter 2018 financial results and provides business update

Read more

Press Release - Life Sciences & Biotechnologie - 26/10/2018

Read more

argenx announces new cusatuzumab (ARGX-110) AML data in abstracts

Read more

Revolutionizing Next-Generation Sequencing (3rd edition)

Read more

Next-Generation Protein Analysis and Detection (3rd edition)

Read more

argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)

Read more

Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Read more

argenx to Present at 37th Annual J.P. Morgan Healthcare Conference

Read more

SCK•CEN Space summer school

Read more

Invitation: Life-on-chip event

Read more

argenx announces closing of exclusive global collaboration and license agreement for cusatuzumab (ARGX-110) with Janssen

Read more

Preservation of micro-organisms: a practical approach

Read more

Thank you for attending!

Read more

BioTech meets Digital

Read more

Daily Newsflash - 11/03/2019

Read more

ProPharma Group Announces the Acquisition of Southwood Research

Read more

Benelux Precision Medicine Forum

Read more

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY

Read more

GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)

Read more

Regional scientific associations bring together researchers from industry and universities

Read more

flanders.health Personalised Medicine event

Read more

Registration open for the flanders.health partnering event on Personalised Medicine (28/05)

Read more

Confo Therapeutics raises €30 million in Series A financing

Read more

Promethera Biosciences Completes €39.7 Million ($44.4 Million) Series D Financing

Read more

Terrific year for Belgian biotech companies

Read more

flanders.health Personalised Medicine event (28/11, Leuven)

Read more

Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies

Read more

Invitation: Second edition Hot in Healthcare

Read more

Hot in Healthcare

Read more

Daily Newsflash - 07/06/2019

Read more

How to Hold Your First-In-Human Trial?

Read more

Gilead announces intent to submit new drug application for filgotinib to U.S. food and drug administration this year

Read more

Gilead and Galapagos enter into transformative research and development collaboration

Read more

Women Startup Challenge Europe HealthTech

Read more

European Business Development Conference 2019

Read more

BioFIT 2019

Read more

MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group

Read more

MDxHealth and Queensland University of Technology Collaborate on Oral Cancer Liquid Biopsy Test

Read more

flanders.bio strenghtens its team with the appointment of 3 Programme Managers

Read more

Biocartis Group NV: Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection

Read more

BioSeed® 2017

Read more

BioSeed 2019

Read more

ONTOFORCE wins the EIT Venture Award 2017

Read more

SLAS Europe 2018

Read more

Course: Radiation-induced effects with particular emphasis on genetics, development, teratology, cognition as well as space-related health issues

Read more

OPINNO

Read more

Capricorn Venture Partners stapt in kapitaal van ViroVet NV

Read more

CMAST to present at a Veeva seminar on modernizing quality management / April 10th, 2018 / Paris, France

Read more

The first veterinary stem cell product recommended for approval in Europe becomes a reality

Read more

Biocartis Group NV: Studies on Idylla(TM) MSI and RAS liquid biopsy tests to be presented at ESMO congress

Read more

eTheRNA: Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL

Read more

de clercq & partners annual ip seminar

Read more

flanders.bio is an independent member-driven life sciences cluster organisation in Flanders (Belgium - EU)

Read more

Winnaar van de Dr. Paul Janssen Award voor Biomedisch Onderzoek bekend

Read more

Expertise

Read more

VITO sterk in ontwikkeling van dierproefvervangende testmethoden

Read more

ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP

Read more

Ablynx announces positive data from its Japanese ethno-bridging study of Caplacizumab

Read more

MDxHealth Epigenetic Biomarkers Identify Men at Increased Risk of Prostate Cancer Recurrence

Read more

Scientists expose protein responsible for allergic diseases

Read more

OPINNO educational module Antwerp: Get to know the life sciences industry and its various job opportunities

Read more

Celyad Announces Third Quarter 2017 Business Update

Read more

Daily newsflash - 09/11/2018

Read more

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Read more

Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis

Read more

Ablynx commences dosing in its Phase II Study of ALX-0171 in hospitalised Japanese infants with a RSV infection

Read more

Ablynx completes patient recruitment in the Phase IIb Respire Study of its inhaled anti-RSV Nanobody ALX-0171

Read more

Convert Pharmaceuticals appoints Mariola Söhngen as new CEO

Read more

eTheRNA immunotherapies completes patient enrolment for Phase Ib-study in adjuvant melanoma

Read more

Daily newsflash - 07/06/2018

Read more

International recognition for Dirk Inzé

Read more

Internationalisation - FUND

Read more

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

Read more

Innovative software Moon autonomously diagnoses rare diseases within minutes

Read more

MDxHealth: SelectMDx Study Demonstrates Cost-effectiveness in US Healthcare System

Read more

BioBusiness Summer School

Read more

Daily Newsflash- 23/06/17

Read more

Daily Newsflash - 25/03/2019

Read more

Daily Newsflash- 19/06/17

Read more

Daily Newsflash - 27/09/2018

Read more

Daily newsflash - 19/11/2018

Read more

Daily newsflash - 23/11/2018

Read more

Services

Read more

MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients

Read more

ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

Read more

Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient

Read more

Biocartis launches innovative Idylla(TM) MSI Assay

Read more

ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study

Read more

Plant immunity cut to size

Read more

Daily Newsflash - 05/04/2019

Read more

Newsflash

Read more

Questionnaire: lifelong learning for Industrial Engineers Biochemistry

Read more

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Read more

MDxHealth (R): SelectMDx improves prostate biopsy decision-making in urology practices

Read more

MDxHealth Announces Positive Data from Pan-European Clinical Validation Study of SelectMDx

Read more

Data Transparency in Pharma R&D - Update on Policy 70 and first practical experiences

Read more

12th Conference on Protein Stabilization (ProtStab 2018)

Read more

ViroVet wins “start-up of the year” award

Read more

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Read more

Celyad Announces First Quarter 2017 Business Update

Read more

VIB: New genes found only in humans shed light on unique features of brain development

Read more

2017 IIBN Forum - Biotechnology: from Innovation to Industrial Production

Read more

ELIXIR Innovation and SME Forum

Read more

NEW EARLY PHASE CLINICAL TRIALS PARADIGM - 6TH BIOPHARM DAY SEMINAR

Read more

Development of a new leishmaniasis drug wins EU funding

Read more

Navarra-Flanders Global Business Bridges

Read more

ConfirmMDx Featured in OncologyLive Magazine

Read more

Emerging Applications of Microbes

Read more

Press Release - Life Sciences & Biotechnology - 17/01/2018

Read more

Persbericht - Life Sciences & Biotechnologie - 17/01/2018

Read more

Call for candidacies for the Board of Directors of flanders.bio

Read more